中国证券报：国内公募产品总规模已突破35万亿元，在满足投资者财富管理需求等方面发挥了重要作 用。请介绍一下公募产品的布局现状，未来是否还有优化空间？ 中证报中证网讯(记者王雪青)公募基金的高质量发展，需要全面提升资产配置与管理能力，满足不同投 资者日益多元的需求。其中，产品结构不断丰富与优化至关重要。针对公募基金行业的产品布局现状， 投资者的期待以及未来发展机遇等话题，中国证券报记者采访了长盛基金量化投资部兼产品开发部总经 理梁洁琼。 编者按：今年5月，中国证监会发布《推动公募基金高质量发展行动方案》，为行业发展指明了方向。 在《行动方案》指导下，基金公司将面临哪些机遇与挑战，对普通投资者有何影响和意义？针对上述问 题，中国证券报邀请了长盛基金多位相关管理人员，分别围绕公募行业费率改革，投资者陪伴模式的创 新，平台式、一体化、多策略投研体系的建设，公募考核体系强化与投资者利益绑定，国内公募产品类 型及未来产品方向，践行信义责任、建设完善的合规风控体系等核心问题，分享观点和思考。本文为系 列访谈之四。 梁洁琼：国内公募基金行业已迈入规模化、多元化发展新阶段，公募产品品类创新与边界拓展持续深 化。一是产品分类更精 ...

■ 苏向杲 9月25日，宁德时代股价盘中突破400元整数关口，总市值一度超越贵州茅台，引发市场广泛关注。今年 以来，A股科技板块持续活跃，而部分传统行业板块表现相对平淡，不同板块之间的市值呈现"此消彼 长"态势，持续重塑着市场结构。 近日，中国证监会主席吴清在国新办新闻发布会上指出，目前A股科技板块市值占比超过1/4，已明显高 于银行、非银金融、房地产行业市值合计占比。市值前50名公司中科技企业从"十三五"末的18家提升至 当前的24家。 笔者认为，A股市场市值格局的演变，清晰反映了我国经济转型的路径。进一步看，这一变化折射出三 大新趋势。 其一，科技革命成为驱动增长的新引擎。 以往，金融、地产和传统资源类企业是市场的市值支柱，其高占比反映出投资拉动的增长模式。当前， 科技板块市值占比持续提升，新能源、人工智能、生物医药等新兴产业公司市值快速攀升，标志着中国 经济正加速转向创新驱动。这一转变顺应全球科技与产业变革趋势，表明新质生产力已在资本市场扎 根，经济增长动能加速转换，发展韧性不断增强。 尤其值得注意的是，今年A股市值格局的变化，不仅源于市场预期的转向，更有扎实的业绩作为支撑。 2025年上半年，创业板、 ...

其一，科技革命成为驱动增长的新引擎。 ■苏向杲 9月25日，宁德时代（300750）股价盘中突破400元整数关口，总市值一度超越贵州茅台（600519），引 发市场广泛关注。今年以来，A股科技板块持续活跃，而部分传统行业板块表现相对平淡，不同板块之 间的市值呈现"此消彼长"态势，持续重塑着市场结构。 近日，中国证监会主席吴清在国新办新闻发布会上指出，目前A股科技板块市值占比超过1/4，已明显高 于银行、非银金融、房地产行业市值合计占比。市值前50名公司中科技企业从"十三五"末的18家提升至 当前的24家。 笔者认为，A股市场市值格局的演变，清晰反映了我国经济转型的路径。进一步看，这一变化折射出三 大新趋势。 以往，金融、地产和传统资源类企业是市场的市值支柱，其高占比反映出投资拉动的增长模式。当前， 科技板块市值占比持续提升，新能源、人工智能、生物医药等新兴产业公司市值快速攀升，标志着中国 经济正加速转向创新驱动。这一转变顺应全球科技与产业变革趋势，表明新质生产力已在资本市场扎 根，经济增长动能加速转换，发展韧性不断增强。 尤其值得注意的是，今年A股市值格局的变化，不仅源于市场预期的转向，更有扎实的业绩作为支撑 ...

Asia Quantitative Strategy China Next Winners: Repeating the Alpha Playbook Rupal Agarwal +65 6326 7641 rupal.agarwal@bernsteinsg.com Cheng Zhang, CFA, CQF +852 2123 2636 cheng.zhang@bernsteinsg.com This report is part of a series on China Next Winners in which we identify the next generation of industries and corporate winners in China. We present an alpha playbook deriving systematic insights from the past for the future. Five-year plan, a useful guide: In the run-up to the 15th five-year plan to be annou ...

Core Viewpoint - The recent release of the "National Drug Centralized Procurement Document" by the National Organization for Drug Procurement has sparked widespread attention and discussion in the pharmaceutical industry, indicating a shift towards innovation-driven development rather than just low-cost generics [1] Group 1: Changes in Procurement Rules - The new procurement rules emphasize "rational pricing" rather than just "soulful price cuts," aiming to address previous concerns about extreme low pricing that could harm quality [2] - The introduction of a new price control mechanism based on "50% of the average price of shortlisted bids" instead of the lowest bid aims to prevent companies from quoting prices below cost [2][3] - A requirement for companies to submit a "Price Reasonableness Declaration" if their bid is below the anchor price is intended to ensure that pricing reflects actual costs and quality considerations [3] Group 2: Impact on Market Dynamics - The introduction of the "brand-based reporting mechanism" allows medical institutions to report expected usage by specific brands, aligning procurement more closely with clinical needs and reducing discrepancies between reported and actual demand [6] - The new rules are expected to enhance the precision and execution of procurement processes, addressing issues of inflated reporting and resource wastage [6] Group 3: Quality Control and Compliance - The new procurement rules raise the bar for quality control, requiring companies to have at least two years of experience in producing similar formulations and compliance with GMP standards [7] - The regulatory framework includes a "first report leniency" mechanism to encourage companies to report any irregularities, promoting a culture of compliance and transparency [8] - The National Medical Products Administration has achieved a 100% pass rate in drug inspections for key procurement varieties, indicating a strong focus on maintaining drug quality [8]

Core Insights - ASEAN countries have seen a 70% increase in patent applications over the past decade, indicating rapid growth in intellectual property within the region [1] - The rise in patent applications is attributed to significant improvements in innovation capabilities among ASEAN member states [1] - ASEAN is focusing on intellectual property as a strategic support for economic growth, innovation, and regional integration, aiming for a transition to a high-value, innovation-driven economy by 2045 [1] Summary by Categories Intellectual Property Growth - Patent applications in ASEAN have increased by 70% in the last ten years [1] - Industrial design patent applications have risen by 80%, while trademark applications have increased by over 10% [1] - There are currently over 50 unicorn companies in the ASEAN region [1] Innovation and Economic Strategy - Three ASEAN member countries have entered the ranks of the world's leading innovative nations [1] - ASEAN is leveraging intellectual property as a catalyst for innovation, inclusivity, and sustainable growth [1] - The region aims to build a resilient, innovative, and people-centered organization by 2045 [1]

Core Insights - The recent release of the "National Drug Centralized Procurement Document" by the National Organization for Drug Procurement has sparked significant attention and discussion within the pharmaceutical industry, particularly due to multiple adjustments in the procurement rules [1] - The principle of "no new drugs in centralized procurement" has been reiterated, indicating that innovative drugs will not be included in the procurement process, which has led to a temporary surge in the capital market [1] - The adjustments signal a strong shift in China's pharmaceutical industry from "generic low prices" to "innovation-driven" development [1] Group 1: Changes in Procurement Rules - The latest procurement rules emphasize rational pricing rather than solely focusing on low prices, addressing previous concerns about extreme low pricing practices that could harm quality [2][3] - The introduction of a new price control mechanism based on "50% of the average bid" rather than the lowest bid aims to prevent companies from underbidding to win contracts, thus promoting a more balanced competition [2][3] - A requirement for companies to submit a "Price Reasonableness Declaration" if their bids are below the established price point is intended to ensure that pricing reflects actual costs and quality considerations [3] Group 2: Impact on Market Dynamics - The introduction of the "brand-based reporting" mechanism allows medical institutions to report expected usage by specific brands, aligning procurement more closely with clinical needs and reducing discrepancies between reported and actual demand [4][5] - This change is expected to influence companies' pricing strategies and market predictions significantly, as it will better match supply with actual clinical usage [4][5] - The new rules also raise the qualification thresholds for bidders, requiring at least two years of production experience and compliance with GMP standards, thereby enhancing the overall quality of products in the market [6] Group 3: Regulatory Enhancements - The regulatory framework has been strengthened with comprehensive checks and product sampling to ensure the quality of selected drugs, with a 100% pass rate reported for recent inspections [6] - The introduction of a "first report leniency" mechanism encourages companies to report any irregularities in bidding practices, promoting transparency and accountability within the procurement process [6] - The evolution of these procurement rules is viewed as a significant indicator of the government's commitment to building a stable, efficient, and sustainable pharmaceutical supply system, moving from aggressive price reductions to long-term stability [6]

Group 1 - The company expects a net profit attributable to shareholders of 340 million to 420 million yuan for the first three quarters of 2025, representing a year-on-year increase of approximately 140 million to 220 million yuan, or a growth of 69.81% to 109.77% [1] - The main reason for the performance change is the adjustment in sales strategy, leading to a steady increase in foreign trade market share, with PVA export volume increasing by over 40%, and acetic acid methyl ester export volume increasing by around 30% [1] - The company has focused on high value-added new materials in the PVA downstream sector, enhancing R&D investment and overcoming technical barriers, resulting in significant sales and profitability growth for new materials like PVA optical films [1] Group 2 - The company's revenue composition for the first half of 2025 is as follows: chemical industry 61.32%, new materials 22.99%, building materials 7.75%, chemical fiber 4.1%, and other businesses 3.84% [1] - The decline in prices of raw materials such as coal, acetic acid, and PTA has led to an increase in gross margins for products like PVA and polyester chips, enhancing profitability [1] - The company has strengthened cost control and steadily advanced cost reduction and efficiency improvement, leading to continuous enhancement of operational efficiency [1]

Group 1: Company Overview - Baiyun Electric Group has transformed from a rural "blacksmith shop" into a leading enterprise in the domestic power equipment manufacturing sector, showcasing strong vitality in technological innovation and high-quality development [2][3] - The company has implemented a pragmatic innovation strategy, leading to significant technological breakthroughs in various projects, including a new type of distribution network demonstration project [2][3] Group 2: Technological Advancements - Baiyun Electric has developed a "light storage and flexible charging" project, achieving a photovoltaic conversion rate improvement of nearly 30% and establishing itself as an industry benchmark [2][3] - The company has integrated various new technologies, such as gel and matrix material systems, into its products, enhancing its capabilities in power electronics and direct connections to 10 kV power grids [2][3] Group 3: Industry Impact - Baiyun Electric has established a complete upstream and downstream industrial chain, contributing to the high-quality development of the power storage industry [4] - The company has received multiple awards, including the National Science and Technology Progress Award and the China Patent Award, reflecting its commitment to innovation and excellence [3][4] Group 4: Market Position and Future Plans - Baiyun Electric is actively expanding its influence by establishing innovation parks and collaborating with various enterprises to foster a synergistic development model [4] - The company aims to continue its focus on the power energy service sector, positioning itself as a national-level specialized technology enterprise [3][4]

Core Insights - The pharmaceutical industry is experiencing a resurgence driven by innovation, favorable policies, and an aging population, positioning it as a key investment opportunity [2][5][6] Historical Market Review - The pharmaceutical sector has undergone multiple market cycles over the past fifteen years, with significant performance variations influenced by unique driving factors [2] - From 2009 to 2010, the industry saw a substantial rebound due to the "four trillion" policy, resulting in a 148.46% increase in the CSI Pharmaceutical Index, outperforming the Shanghai Composite Index's 54.22% rise [2][3] - Between 2013 and 2015, the sector faced stricter regulations, leading to a mixed performance where it did not outperform the ChiNext Index, although new themes like smart healthcare gained traction [3] - The period from 2019 to 2021 was marked by a strong performance driven by the pandemic, with the CXO Index surging 277.13% [3] - In 2024, the pharmaceutical sector faced challenges, with the CSI Pharmaceutical Index declining 14.53%, underperforming the CSI 300 Index [4] Current Investment Value Analysis - The current valuation of the pharmaceutical sector is considered reasonable after prior adjustments, with some indices showing attractive investment metrics [5] - Leading pharmaceutical companies are expected to maintain stable growth due to the commercialization of innovative drugs and steady performance in traditional drug segments [5] - The aging population is projected to drive increased healthcare demand, with 22.0% of the population aged 60 and above by the end of 2024 [5] - There has been a notable inflow of funds into the medical device sector, indicating growing market confidence in certain pharmaceutical sub-sectors [5][6] Policy Environment - The policy focus is shifting from cost control to innovation-driven growth, with reforms in the medical insurance payment system and expedited drug approval processes [6] - The National Medical Insurance Administration plans to expand the medical insurance drug list, which will benefit the industry's innovation and profitability [6] Innovation in Pharmaceuticals - Innovative drugs are becoming the focal point of the Chinese pharmaceutical industry, with significant advancements in areas like oncology and antibody-drug conjugates [7] - The total value of license-out deals for Chinese innovative drugs surpassed $60 billion in the first half of 2025, indicating a strong international presence [7] Investment Participation Strategies - Investors are encouraged to adopt a systematic investment approach to mitigate short-term volatility, as the pharmaceutical sector is characterized by long-term growth potential [9] - Focus on sectors with strong policy support and international expansion opportunities, such as innovative drugs and medical devices, is recommended [9]